Prolactin response to growth hormone-releasing hormone during chronic thyrotropin-releasing hormone infusion in the treatment of amyotrophic lateral sclerosis

Journal of Endocrinological Investigation
P G ChiodiniD Testa

Abstract

In six patients suffering from amyotrophic lateral sclerosis we evaluated changes of T4, T3, TSH, PRL, and GH during treatment by continuous iv infusion of TRH for at least 15 days. No clinical improvement was detected. A significant rise of thyroid hormone levels was observed, as well as an upward trend of basal TSH levels and no change of basal PRL and GH levels. TRH acute test-induced TSH and PRL responses became blunted. Treatment provoked also the onset of a responsiveness of PRL to GHRH. The reduced TSH and PRL responses to acute TRH test during treatment could be explained by a down-regulation of TRH pituitary receptors. On the contrary, the onset of PRL responsiveness to GHRH is at present without a satisfactory explanation.

References

Jul 1, 1977·The Journal of Clinical Endocrinology and Metabolism·G N BurrowR K Donabedian
Sep 1, 1989·Journal of Endocrinological Investigation·R R DaviesD G Johnston
Feb 1, 1986·The Journal of Clinical Endocrinology and Metabolism·A E SmalsP W Kloppenborg
Aug 1, 1987·Journal of Endocrinological Investigation·J A GoldmanS Reichlin
Aug 1, 1984·The Journal of Clinical Endocrinology and Metabolism·M C GelatoG R Merriam
Sep 1, 1983·The Journal of Clinical Endocrinology and Metabolism·S M RosenthalM M Grumbach
May 1, 1984·The Journal of Clinical Endocrinology and Metabolism·M L VanceS Bloom
Aug 1, 1984·Clinical Endocrinology·P E BelchetzF Harris

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.